Postoperative Rise of Circulating Mitochondrial DNA Is Associated with Inflammatory Response in Patients following Pancreaticoduodenectomy

Niv Pencovich    Nadav Nevo    Roi Weiser    Ekaterina Bonder    Yoel Bogoch
Ido Nachmany
Department of General Surgery B, Division of Surgery, Tel-Aviv Sourasky Medical Center, The Nikolas and Elizabeth Shlezak Fund for Experimental Surgery, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Keywords
Mitochondria · DAMPs · SIRS · Pancreatic surgery

Abstract
Introduction: Accumulation of plasma mitochondrial DNA (mtDNA) following severe trauma has been shown to correlate with the development of systemic inflammatory response syndrome (SIRS) and may predict mortality. Our objective was to investigate the relationship between levels of circulatory mtDNA following pancreaticoduodenectomy (PD) and the postoperative course. Methods: Levels of plasma mtDNA were assessed by real-time PCR of the mitochondrial genes ND1 and COX3 in 23 consecutive patients who underwent PD 1 day prior to surgery, within 8 h after surgery, and on postoperative day (POD)1 and POD5. The abundance of mtDNA was assessed relative to preoperative levels and in relation to parameters reflecting the postoperative clinical course. Results: When pooled for all patients, the circulating mtDNA levels were significantly increased after surgery. However, while a significant (at least >2-fold and up to >20-fold) rise was noted in 11 patients, no change in mtDNA levels was noted in the other 12 following surgery. Postoperative rise in circulating mtDNA was associated with an increased rate of postoperative fever until day 5, decreased hemoglobin and albumin levels, and increased white blood cell counts. These patients also suffered from increased rates of delayed gastric emptying. No significant differences were demonstrated in other postoperative parameters. Conclusion: Circulating mtDNA surge is associated with an inflammatory response following PD and may potentially be used as an early marker for postoperative course. Studies of larger patient cohorts are warranted.

Introduction
Abdominal surgery triggers an inflammatory response, the magnitude of which usually correlates with the extent of the surgical trauma [1–3]. Following major surgery, an initial hyperinflammatory response may evolve into systemic inflammatory response syndrome (SIRS), and occasionally lead to multiple organ dysfunction syndrome (MODS) [4, 5]. It was previously shown that early development of SIRS after surgery is associated with an adverse postoperative clinical course, a higher rate of severe morbidity, and early postoperative mortal-
ity [6–9]. Detection of patients at risk of postoperative SIRS may allow for prompt intervention and potentially improves outcome [9, 10]. Unfortunately, early markers of inflammation that can indicate an upcoming complication are not readily available.

Studies have shown that severe trauma induces the release of mitochondrial damage-associated molecular patterns (DAMPs), consisting of mitochondrial DNA and formyl peptides [11–14]. Mitochondrial DAMPs directly activate polymorphonuclear cells, leading to a sepsis-like state and neutrophil-mediated organ injury [11–14]. Moreover, following severe trauma, an increased level of circulating mitochondrial DNA (mtDNA) DAMPs has been associated with the development of acute respiratory distress syndrome (ARDS), SIRS, MODS, and mortality [14–17]. A postoperative surge of circulating mtDNA following major abdominal surgery such as pancreaticoduodenectomy (PD) which, by necessity, is associated with tissue trauma, may play a role in the development of postoperative SIRS and other consequent complications.

We assessed whether postoperative levels of circulating mtDNA are associated with the clinical course of patients who underwent PD for borderline resectable pancreatic adenocarcinoma (PDAC).

Materials and Methods

Patients

Included in this prospective cohort study are 23 patients that underwent PD for borderline resectable PDAC [18] between December 2014 and March 2016. Until recently, neoadjuvant treatment was not routine for borderline resectable PDAC and none of the patients received preoperative chemotherapy. Also, our policy was to avoid preoperative biliary interventions to reduce infectious and inflammatory complications, so no patient underwent preoperative biliary drainage. Therefore, no inflammatory events such as pancreatitis or cholangitis occurred prior to surgery. The mean preoperative serum amylase level was 89 ± 37 U/L and no patient had levels above the normal values. Demographics and preoperative data were evaluated and graded using the Clavien-Dindo (CD) classification of surgical complications [19]. Specific PD-related complications such as delayed gastric emptying, pancreatic fistula, postpancreatectomy hemorrhage (PFH), etc. were also assessed. SIRS was defined according to the American College of Chest Physicians (ACCP)/Society of Critical Care Medicine (SCCM) definition [20]. MODS was defined as a Denver postinjury multiple-organ failure score of ≥4 [21]. This scoring system rates the dysfunction of 4 organ systems (i.e., pulmonary, renal, hepatic, and cardiovascular) which are assessed daily during a patient’s stay in the intensive care unit (ICU).

Statistical Analysis

Statistical analysis was performed using the IBM SPSS statistics data editor v25. Continuous data are expressed as median values with the corresponding SD. Student’s t test was used for continuous data and the χ² test for categorical data. Patients were divided into those with and without a significant increase in mtDNA following surgery, a sample size of at least 10 patients in each group was sufficient for 0.8 power with at least 10% difference (α = 0.05) in the blood indices (continuous parameters) examined. p < 0.05 was considered statistically significant.

Results

Between December 2014 and March 2016, 23 patients (7 females; mean age 67 years, range 46–83 years) underwent an elective pancreatic resection for borderline resectable PDAC by an open approach. Patient characteristics as well as operative and postoperative data are supplied in Table 1. The average operative time was 444 ± 161 min (range 312–798 min) and mean estimated blood loss was 245 ± 170 mL. Three patients received packed cells during surgery (1 received 2 units and 2 received 1 unit each). In 7 patients, superior mesenteric vein/portal vein resection and reconstruction were required to achieve complete tumor extirpation. All patients were admitted to the ICU following surgery. Average time in
**Table 1.** Patient demographics and operative characteristics

|                          | All patients (n = 23) | Postop mtDNA increase (n = 11) | No mtDNA increase (n = 12) | p value |
|--------------------------|-----------------------|-------------------------------|---------------------------|---------|
| Age, years               | 67.4±9.6              | 69.4±8.2                      | 65.5±10.3                 | 0.35    |
| Males/females, n (ratio) | 16/7 (2.28)           | 7/4 (1.75)                    | 8/3 (2.6)                 | 0.72    |
| BMI                      | 25.1±4                | 25.8±3.7                      | 24.4±4.2                  | 0.44    |
| Comorbidity              |                       |                               |                           |         |
| HTN                      | 12 (52.1)             | 7 (63.6)                      | 5 (41.6)                  | 0.29    |
| DM                       | 12 (52.1)             | 7 (63.6)                      | 5 (41.6)                  | 0.29    |
| IHD                      | 3 (13)                | 2 (18.1)                      | 1 (8.3)                   | 0.48    |
| CKD                      | 1 (4.3)               | 1 (9)                         | –                         | –       |
| COPD                     | 2 (8.6)               | 2 (18)                        | –                         | –       |
| Prior abdominal surgery  | 7 (30.4)              | 2 (18)                        | 5 (41.6)                  | 0.22    |
| Duration of surgery, min | 444±161               | 462±148                       | 428±170                   | 0.063   |
| Pyloric preservation     | 11 (47.8)             | 4 (36.3)                      | 7 (58.3)                  | 0.29    |
| Estimated blood loss, mL | 252±166               | 318±203                       | 191±86                    | 0.04    |
| Blood transfusion        | 3 (13)                | 2 (18)                        | 1 (8.3)                   | 0.28    |
| Vascular resection       | 10 (43.4)             | 5 (45.4)                      | 5 (41.6)                  | 0.95    |
| Extubated at the end of surgery | 15 (65) | 6 (54)                        | 9 (75)                    | 0.35    |

Values are expressed as n (%) or mean ± SD, unless otherwise indicated. BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; IHD, ischemic heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
ICU was 2.6 days (range 1–17 days). Nine patients had SIRS during the first 5 days following surgery, but no patient had MODS. Six patients (26%) suffered from major postoperative complications (CD ≥3), while 17 had either minor (CD <3) complications or an uneventful course. Two patients (8.6%) underwent reoperation during the immediate postoperative course. Mean length of hospital stay was 12 ± 3 days (range 8–21 days). One patient was rehospitalized within 30 days of surgery. There was no 30-day mortality. In all patients, an R0 resection was achieved.

Peripheral blood was drawn prior to surgery, within 8 h from operation, on POD1 and POD5. For each patient, mtDNA levels, depicted by the mitochondrial genes ND1 and COX3, were quantified at the indicated time points as PCR threshold cycle (Tc), with each cycle doubling the DNA quantity until a detection threshold is achieved. mtDNA levels were also assessed as fold-change in relation to preoperative levels (Fig. 1). Overall, the mean mtDNA levels were significantly increased 8 h after surgery, on POD1 and POD5, compared to the preoperative levels (ND1: POD0, POD1, and POD5 fold-changes of 2.38 ± 7.85, 2.85 ± 7.85, and 2.44 ± 9.12; COX3: POD0, POD1, and POD5 fold-changes of 4.03 ± 11.6, 3.73 ± 7.1, and 3.9 ± 8.8, respectively; Fig. 1).

In 11 patients, the levels of circulating mitochondrial DNA increased significantly already on POD1 (at least >2-fold) compared to control levels (Fig. 2), while in the other 12 patients, no increase was demonstrated.

No significant differences in age, gender, body mass index (BMI), and comorbidities were noticed between the groups (Table 1). Patients with a postoperative rise in circulating mtDNA bled more during surgery but did not require excess amount of blood units. Other operative parameters including procedure length, the need for vascular resection, pyloric preservation, and ability to undergo extubation at the end of surgery were all comparable between the groups.

Postoperative increases in circulating mtDNA were associated with higher rates of postoperative fever, up until POD5, decreased hemoglobin levels, increased white blood counts, and decreased albumin levels (Table 2). These patients also suffered from increased rates of delayed gastric emptying. The rate and severity of other postoperative complications including pulmonary complications, surgical-site infection, pancreatic fistula, PPH,
the need for reoperation, and others were comparable between the groups. No difference in the overall length of stay was found between the groups.

**Discussion**

Recent reports showed that elevation of circulating mtDNA DAMPs following severe trauma triggers an inflammatory response by activating circulating polymorphonuclear (PMN) cells via pattern recognition receptors (PRR) including toll-like receptor 9 (TLR9) [11, 12, 22], and is associated with adverse patient outcome [11, 14, 23]. Simmons et al. [14] established a striking correlation between an early mtDNA rise in severely injured patients and later SIRS, MODS, and even mortality. This was supported by other reports demonstrating that increased levels of circulating mtDNA were associated with the development of respiratory distress syndrome in trauma and sepsis patients [17] as well as mortality of ICU patients [24]. This raised the possibility of using mtDNA as a biomarker for the early detection of patients at risk of developing a hyperstimulated inflammatory response and adverse outcomes.

The goal of this study was to assess whether an elective surgery, which consists of significant but controlled tissue trauma, induces a surge of circulating mtDNA that correlates with SIRS and postoperative clinical course. Aiming to provide a preliminary proof of concept, we sought patients who underwent a reproducible major surgery that included extensive tissue dissection and organ resection. Open PD is a high-magnitude surgery, among the most complicated in general surgery, requires a relatively large abdominal incision, a wide tissue dissection, and re-

| Table 2. Postoperative course |
|------------------------------|
|                             | All patients (n = 23) | mtDNA increase (n = 11) | No mtDNA increase (n = 12) | p value |
| Fever until POD5 (%)        | 8 (34.7)             | 6 (54.5)                | 2 (16.6)                   | 0.05    |
| Preoperative, g/dL          | 11.97±1.97           | 12.26±1.43              | 11.87±1.03                 | 0.39    |
| POD1, g/dL                  | 10.6±1.67            | 9.85±1.4                | 11.2±1.44                  | 0.048   |
| POD3, g/dL                  | 10.27±1.6            | 9.3±1.62                | 10.83±1.66                 | 0.047   |
| POD5, g/dL                  | 10.48±1.4            | 9.84±1.34               | 10.9±0.97                  | 0.07    |
| WBC count                   |                     |                         |                           |
| Preoperative, 10^3/μL       | 9.18±2.38            | 8.64±1.93               | 9.57±2.59                  | 0.43    |
| POD1, 10^3/μL               | 14.9±5.7             | 17.46±6.99              | 12.6±2.61                  | 0.042   |
| POD3, 10^3/μL               | 12.02±5.02           | 14.4±5.07               | 10.02±3.17                 | 0.043   |
| POD5, 10^3/μL               | 11.2±4.36            | 13.15±5.11              | 9.38±2.39                  | 0.047   |
| Albumin level               |                     |                         |                           |
| Preoperative, g/L           | 36.4±3.9             | 36.17±5.87              | 37.3±2.21                  | 0.57    |
| POD1, g/L                   | 26±3.9               | 24.3±4.05               | 27.4±3.1                   | 0.046   |
| POD3, g/L                   | 25.2±3.5             | 23.7±2.96               | 26.6±3.4                   | 0.041   |
| POD5, g/L                   | 26.18±3              | 25.1±2.6                | 27.08±3.3                  | 0.13    |
| Pulmonary complications (%) | 5 (21.7)             | 3 (27.2)                | 2 (16.6)                   | 0.65    |
| Delayed gastric emptying (%)| 9 (39.1)             | 7 (63.6)                | 1 (16.6)                   | 0.02    |
| Pancreatic fistula (%)       | 4 (17.3)             | 2 (18)                  | 2 (16.6)                   | 0.92    |
| Postpancreatic hemorrhage (%)| 2 (8.7)              | 1 (9)                   | 1 (8.3)                    | 0.95    |
| Leak of enteric/biliary anastomosis (%) | 1 (4.35) | 0 | 1 (8.3) | – |
| Postoperative complications |                     |                         |                           |
| CD ≥3                       | 6 (26)               | 2 (18)                  | 4 (33.2)                   | 0.4     |
| CD <3                       | 9 (39.1)             | 4 (36)                  | 5 (41.6)                   | 0.8     |
| Surgical wound infection (%)| 4 (17.3)             | 1 (9)                   | 3 (0.25)                   | 0.31    |
| Acute renal failure (%)      | 1 (4.35)             | 1 (9)                   | 0                         | –       |
| Reoperation (%)              | 2 (8.7)              | 1 (9)                   | 1 (8.3)                    | 0.95    |
| Length of hospital stay, days| 11.95±3              | 11.8±3.61               | 12.09±2.27                 | 0.84    |

Values are expressed as n (%) or mean ± SD. Hb, hemoglobin; WBC, white blood cells; CD, Clavien-Dindo scale.
section of organs including the pancreas, duodenum, and bile duct. Moreover, this surgery is highly structured, with little variation between cases. This makes PD ideal for studying variations between patients in response to trauma. We specifically chose borderline resectable cases. These usually require an even wider tissue dissection, especially in cases in which vascular resection is needed. Even though the tissue trauma in elective surgery occurs in a controlled setting, we believe that the release, effect, and sequestration of DAMPs in such settings may differ between patients and affect the clinical course. Evaluating the mtDNA plasma levels preoperatively, 8 h after surgery, and on POD1 and POD5 corresponded with the study designs of Simmons et al. [14] and McIlroy et al. [25].

When pooled for all patients, the circulating mtDNA levels increased >2-fold following surgery, starting within 8 h after surgery using both markers (the mitochondrial genes ND1 and COX3 [14]). In all patients in whom mtDNA levels increased on POD0, these levels were maintained at POD5. When examined specifically, a clear dichotomy was noted: 12 had no significant rise in mtDNA at any time point examined but the other 11 showed a significant increase (in some, >20-fold). In their original report, Zhang et al. [11] demonstrated that following severe uncontrolled trauma, plasma mtDNA levels were elevated >1,000-fold compared to in healthy individuals. Later reports demonstrated a milder increase of 10- to 30-fold [13, 25], similar to the postoperative rise in some of our patients. Since no differences in demographics, medical history, or any significant surgery-related factors were demonstrated between the groups, it is probable that this rise in mtDNA is related to inherent factors that affect either the release or scavenging of mtDNA. McIlroy et al. [25] demonstrated that, in trauma surgery, the postoperative levels of mtDNA were not associated with markers of tissue necrosis but with surgical invasiveness.

Here, since all patients underwent the same surgery, other yet-to-be-investigated factors must have influenced the sustained mtDNA rise in some of the patients. Since the aim of this study was to evaluate whether an increase in the levels of circulating mtDNA as a response to controlled tissue trauma may relate to the extent of the inflammatory response, we were mainly interested in evaluating the difference between pre- and postoperative levels. Assessing the basal levels of mtDNA in relation to healthy individuals or to various other factors, including demographics, comorbidities, or disease-related factors, was beyond the scope of this study. Nevertheless, in our cohort, the abundance of mtDNA prior to surgery was diverse, as demonstrated by the broad range of PCR cycle of detection (range 17.4–23.9 in ND1 and 15.7–24.7 in COX3). This pattern was also demonstrated in other studies that assessed levels of mtDNA in the plasma of different patient populations; in all, the variance was high [14, 26]. Nonetheless, we could not define any significant correlation between basal mtDNA levels and demographic or disease-related factors. Factors influencing the basal levels of circulating mtDNA warrant a separate study.

The postoperative rise in circulating mtDNA was associated with fever and elevated markers of inflammation including leukocytosis, anemia, and hypoalbuminemia as well as a higher rate of delayed gastric emptying. Delayed gastric emptying is a known complication following PD and is usually associated with other complications, such as anastomotic leak, leading to increased inflammatory response and sepsis [27]. Although these parameters are of great importance and may significantly influence the postoperative course, we were not able to demonstrate differences in overall length of stay or other PD-related complications. We believe this may have been related to both the small cohort size and the fact that some of the PD-associated complications were not necessarily associated with the increased inflammatory response (mainly in patients with a well-drained surgical site). An anastomotic leak is a good example, as in many patients systemic findings were limited. Previous studies have already shown that early increases in other inflammatory markers such as TNFα, IL-6, and C-reactive protein may predict SIRS after an elective abdominal surgery [2]. According to data from mouse models [11, 12], we believe that mtDNA, a DAMP directly related to the extent of tissue injury, may not only be a marker for the development of SIRS but also may play a role in initiating it.

This study has the limitation of a small cohort size. However, the cohort was homogenous in terms of disease burden and extent of surgery. Our aim was to provide an initial proof of concept for the potential use of circulating mtDNA level as an early biomarker of a postoperative inflammatory response.

To conclude, elevation of circulating mtDNA following elective PD is associated with an increased inflammatory response. Further studies, with larger cohorts and other surgical procedures are warranted, to establish circulating mtDNA as an early biomarker of inflammation and postoperative complications in elective surgical procedures.
Statement of Ethics

The study was approved by The Tel-Aviv Sourasky Medical Center Institutional Review Board, approval No. 0740-14-TLV. All patients included in this study signed a written informed consent.

Conflict of Interest Statement

The authors declare that they have no conflicts of interest.

References

1. Andersson R, Andersson B, Andersson E, Eckerwall G, Norden M, Tingstedt B. Immunomodulation in surgical practice. HPB (Oxford). 2006;8(2):116–23.
2. Watt DG, Horgan PG, McMillan DC. Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review. Surgery. 2015 Feb;157(2):362–80.
3. Dimopoulos I, Armaganidis A, Douka E, Mavrou I, Augustatou C, Kopterides P, et al. Tumour necrosis factor-alpha (TNFalpha) and interleukin-10 are crucial mediators in postoperative systemic inflammatory response and determine the occurrence of complications after major abdominal surgery. Cyto kinase. 2007 Jan;37(1):55–61.
4. Lord JM, Midwinter MJ, Chen YF, Belli A, Brohi K, Kovacs EJ, et al. The systemic immune response to trauma: an overview of pathophysiology and treatment. Lancet. 2014 Oct;384(9952):1455–65.
5. Ishikawa M, Nishioka M, Hanaki N, Miyau kichi T, Kashihagi Y, et al. Perioperative immune responses in cancer patients undergoing digestive surgeries. World J Oncol. 2009 Jan;7(7).
6. Comstedt P, Storgaard M, Lassen AT. The Systemic Inflammatory Response Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study. Scand J Trauma Resusc Emerg Med. 2009;17(1):67.
7. Kelly KJ, Greenblatt DY, Wan Y, Rettammel RJ, Winslow E, Cho CS, et al. Risk stratification for distal pancreatectomy utilizing ACS-RJ, Winslow E, Cho CS, et al. Risk stratification for distal pancreatectomy utilizing ACS-RSIRS in acutely hospitalised medical patients: a cohort study. Scand J Trauma Resusc Emerg Med. 2009;17(1):67.
8. Szczepanik AM, Scialo L, Scully L, Walewska E, Siedlar M, Kolodziejczyk P, et al. IL-6 serum levels predict postoperative morbidity in gastric cancer patients. Gastric Cancer. 2011 Aug;14(3):266–73.
9. Retig TC, Verwijrmen L, Dijkstra IM, Boer ma D, van de Garde EM, et al. Postoperative Interleukin-6 Level and Early Detection of Complications After Elective Major Abdominal Surgery. Ann Surg. 2016 Jun;263(6):1207–12.
10. Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance HD, et al. (2015) Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upr egulation of TLR4 and TLR5. Ann Surg. 2015.
11. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010 Mar;464(7285):104–7.
12. Krysko DV, AGostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 2011 Apr;32(4):157–64.
13. Itagaki K, Kaczmarek E, Lee YT, Tang IT, Isal B, Adibnia Y, et al. Mitochondrial DNA released by trauma induces neutrophil extracellular traps. PLoS One. 2015 Mar;10(3):e0120549.
14. Simmons JD, Lee YL, Mulekar S, Kuck JL, Brevard SB, Gonzalez RP, et al. Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects. Ann Surg, 2013 Oct;258(4):591–6.
15. Chou CC, Fang HY, Chen YL, Wu CY, Siao FY, Chou MJ. Plasma nuclear DNA and mitochondrial DNA as prognostic markers in corrosive injury patients. Dig Surg. 2008;25(4):300–4.
16. Bulstrode H, Nicoll JA, Hudson G, Chinnery PF, Di Piero V, Belli A. Mitochondrial DNA and traumatic brain injury. Ann Neurol. 2014 Feb;75(2):186–95.
17. Faust HE, Reilly JP, Anderson BJ, Ittner CA, Forker CM, Zhang P, et al. Plasma Mitochondrial DNA Levels are Associated with Acute Respiratory Distress Syndrome in Trauma and Sepsis Patients. Chest. 2020 Jan;157(1):67–76.
18. Bockhorn M, Uzuonguogu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al.; International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGAPS). Surgery. 2014 Jun;155(6):977–88.
19. Clavien PA, Barkun J, de Oliveira ML, Vauth ey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187–96.
20. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992 Jun;20(6):846–74.
21. Sauer A, Moore EE, Johnson JI, Ciesla DJ, Biffi WL, Banerjee A. Validation of postinjury multiple organ failure scores. Shock. 2009 May;31(5):438–47.
22. Zhang Q, Itagaki K, Hauser CJ. Mitochondri al DNA is released by shock and activates neutrophils via p38 map kinase. Shock. 2010 Jul;34(1):55–9.
23. Yamanouchi S, Kudo D, Yamada M, Miya gawa N, Furukawa H, Kushimoto S. Plasma mitochondrial DNA levels in patients with trauma and severe sepsis: time course and the association with clinical status. J Crit Care. 2013 Dec;28(6):1027–31.
24. Nakahira K, Kyung SY, Rogers AJ, Gazourian L, Youn S, Massaro AF, et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med. 2013 Dec;10(12):e1001577.
25. McIlroy DJ, Bigland M, White AE, Hardy BM, Lott N, Smith DW, et al. Cell necrosis-independent sustained mitochondrial and nuclear DNA release following trauma surgery. J Trauma Acute Care Surg. 2015 Feb;78(2):282–8.
26. Gu X, Yao Y, Wu G, Lv T, Luo I, Song Y. The plasma mitochondrial DNA is an independent predictor for post-traumatic systemic inflammatory response syndrome. PLoS One. 2013 Aug;8(8):e72834.
27. Parmar AD, Sheffield KM, Vargas GM, Pitt HA, Kilbane EM, Hall BL, et al. Factors associated with delayed gastric emptying after pancreaticoduodenectomy. HPB (Oxford). 2013 Oct;15(10):763–72.